CellaVision ABCVLLY +12.06%69 Pretax Margin % is 17.11% as of Mar. 2026, which is 36% below its 10-year median of 26.79. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 817 Medical Devices & Instruments companies, CellaVision AB ranks better than 89.23% on this metric.
The historical rank and industry rank for CellaVision AB's Pretax Margin % or its related term are showing as below:
CVLLY'
s Pretax Margin % Range Over the Past 10 Years
Min: 23.22 Med: 26.79 Max: 30.73
Current: 23.3
CVLLY's Pretax Margin % is ranked better than 89.23% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.43
vs CVLLY: 23.30
CellaVision AB (OTCPK:CVLLY) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
CellaVision AB Pretax Margin % Related Terms
CellaVision AB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVLLY vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, CellaVision AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CVLLY) has a Pretax Margin % of 17.11% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on CellaVision AB and its competitors. This is 36% below median its historical median of 26.79. Over the past decade, CellaVision AB's Pretax Margin % has ranged from 23.22 to 30.73. According to the industry distribution chart, CellaVision AB ranks #88 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 10.8%.
Is CellaVision AB's Pretax Margin % too high?
CellaVision AB's current Pretax Margin % of 17.11% is 36% below median its 10-year median of 26.79. Over the past 10 years, this metric has ranged from a low of 23.22 to a high of 30.73. The Medical Devices & Instruments industry median Pretax Margin % is 2.43. CellaVision AB's value of 17.11% is 604.1% above this industry median. Based on the distribution chart, CellaVision AB ranks #88 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #88 out of 817 companies for Pretax Margin %. This places CellaVision AB in the top 11% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 2.43. CellaVision AB's value of 17.11% is 604.1% above this benchmark. Historically, CellaVision AB's own Pretax Margin % has ranged from 23.22 to 30.73 over the past decade. While the company's 10-year median is 26.79 vs. the industry median of 2.43, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.43, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current Pretax Margin % of 17.11% is 604.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Pretax Margin % is 17.11%, which is 36% below median its own 10-year median of 26.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current Pretax Margin % is 17.11%, which is 36% below median its 10-year median of 26.79 and 604.1% above the Medical Devices & Instruments industry median of 2.43. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current Pretax Margin % is 17.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
Pretax Margin %: 17.11% (36% below median its 10-year median of 26.79)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 604.1% above the Medical Devices & Instruments median (#88 of 817)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
